Targeting the IDO1 pathway in cancer: from bench to bedside.
Targeting the IDO1 pathway in cancer: from bench to bedside.
复制标题
靶向癌症IDO1通路:从实验到临床。
DOI:
10.1186/s13045-018-0644-y
复制
发表时间:
2018-08-02
影响因子:
28.5
通讯作者:
Li Y
中科院分区:
文献类型:
--
作者:
Liu M;Wang X;Wang L;Ma X;Gong Z;Zhang S;Li Y
Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors. Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells. In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance. We highlight recent preclinical and clinical progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymatic inhibitors, and effector inhibitors.
登录
查看更多内容
影响因子:
28.5
作者:
Huang Q;Xia J;Wang L;Wang X;Ma X;Deng Q;Lu Y;Kumar M;Zhou Z;Li L;Zeng Z;Young KH;Yi Q;Zhang M;Li Y
通讯作者:
Li Y
影响因子:
8.8
作者:
Holmgaard RB;Zamarin D;Li Y;Gasmi B;Munn DH;Allison JP;Merghoub T;Wolchok JD
通讯作者:
Wolchok JD
影响因子:
7.3
作者:
Banzola I;Mengus C;Wyler S;Hudolin T;Manzella G;Chiarugi A;Boldorini R;Sais G;Schmidli TS;Chiffi G;Bachmann A;Sulser T;Spagnoli GC;Provenzano M
通讯作者:
Provenzano M
影响因子:
30.5
作者:
Fallarino, F;Grohmann, U;Puccetti, P
通讯作者:
Puccetti, P
影响因子:
4.4
作者:
Hwu, P;Du, MX;Young, HA
通讯作者:
Young, HA